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Functionalized yogurtsNatural ingredients are valuable options to be exploited in the design of innovative food formulations
with health benefits. Therefore, it was evaluated the potential use of Arenaria montana L. hydroethanolic
extract (rich in apigenin derivatives) as a chemopreventive agent in functional foods. Apigenin is recog-
nized as inhibiting VEGFR-2, which is the key receptor involved in angiogenesis. The obtained extract was
also able to inhibit the VEGFR-2 phosphorylation through an enzymatic assay (IC50 = 63 mg/mL).
Thereafter, free and microencapsulated forms were incorporated in yogurt. The obtained products main-
tained the nutritional value along the tested 3 days of storage, as also free sugars and fatty acids profiles,
in comparison with the control samples. Nevertheless, the VEGFR-2 phosphorylation inhibition was not
exhibited as intended. Even this behavior for the microencapsulated forms can be attributed to the pro-
tecting effect of the alginate matrix, further studies are required in order to better understand the shown
performance.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
The growth of new blood vessels from pre-existing ones is
called angiogenesis, which is a fundamental process for embryonic
development as well as normal tissue homeostasis (Patan, 2000).
Under normal physiological conditions, there is a balance between
stimulatory and inhibitory factors that regulates the process of
angiogenesis (Fan, Yeh, Leung, Yue, & Wong, 2006). However, in
pathological cases, like tumor progression, the stimulation
becomes excessive, resulting in the uncontrolled growth of new
vessels, which facilitate tumor development and metastasis,
through the production of abnormally large amounts of angiogen-
esis factors, such as VEGF (vascular endothelial growth factor)
(Saghiri, Asatourian, Orangi, Sorenson, & Sheibani, 2015). The VEGF
is involved in the vascular permeability, as well as in the induction
of endothelial cell proliferation, migration and survival, mainlythrough their membrane receptor tyrosine kinase VEGFR-2 (also
known as KDR) (Soares et al., 2013).
It is recognized that diet contributes to more than 40% of the
chronic angiogenic diseases (Losso, 2007). Nevertheless, foods are
nowadays designed not only for nutritional purposes, but also to
prevent diseases and to improve physical and mental well-being
(Bigliardi & Galati, 2013). Therefore, several studies have been con-
ducted in order to identify functional foods active against excessive
angiogenesis (Losso, 2007).
Plants are recognized as a source of bioactive compounds, for
example phenolic compounds with reported antitumor properties
(Stagos et al., 2012). Arenaria montana L., an herbaceous plant from
the mountainous regions of southwestern Europe (Timité et al.,
2011), contains apigenin derivatives, specifically apigenin
6-C-hexoside-8-C-hexoside, apigenin 6-C-hexoside-8-C-pentoside,
apigenin 200-O-pentosyl-6-C-hexoside, apigenin-6-C-glucoside,
apigenin 200-O-acetylpentosyl-6-C-hexoside and apigenin 200-O-
feruloylhexosyl-6-C-hexoside (Pereira et al., 2014). Apigenin has
received increasing attention due to its bioactive properties
such as anti-inflammatory (Wang & Huang, 2013), anti-mutagenic
(Patel, Modi, Chiosis, & Taldone, 2011) and, particularly,
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He et al., 2015; Johnson & Mejia, 2013). This flavone has shown
the capacity to inhibit the cellular proliferation of several cancer
cell lines such as hepatocellular (Kim, Jeon, & Nam, 2011), pancre-
atic (He et al., 2015; Johnson & Mejia, 2013), colorectal (Banerjee
& Mandal, 2015), multiple myeloma (Zhao et al., 2011) and leuke-
mia (Budhraja et al., 2012), prevent the growth of new blood vessels
(metastasis) (Osada, Imaoka, & Funae, 2004), change themicroenvi-
ronment of the cancer cells growth and reduce the cancer cells
glucose uptake (Lefort & Blay, 2013).
Although appreciated and consumed worldwide, yogurt is a
product with limited amounts of bioactive compounds. This limita-
tion can be overcome, by enrichment with natural extracts from
plants or fruits, as proposed by some authors (Caleja et al., 2016;
Martins et al., 2014). However, these extracts, which contain phe-
nolic compounds and other bioactive molecules, most often are
unstable under environmental and processing conditions, e.g. light,
moisture, temperature and food matrix effects (Dias, Ferreira, &
Barreiro, 2015). Also, they might become inactive after being
metabolized (Heleno, Martins, Queiroz, & Ferreira, 2015). In this
context, microencapsulation, a process through which the bioac-
tive compound is entrapped or covered by a material, allows pro-
tection from these adverse conditions (Dias, Ferreira et al., 2015).
In the present study, the ability of A. montana hydroethanolic
extract (rich in apigenin derivatives) to inhibit the phosphorylation
of VEGRF-2 (enzyme involved in the angiogenesis process) was
evaluated. Thereafter, the extract was microencapsulated using
an atomization/coagulation technique with alginate as the encap-
sulating material. The obtained microspheres were characterized
by optical microscopy (to inspect morphology and size) and the
encapsulation estimated by HPLC-DAD. As a subsequent applica-
tion step, the produced microspheres, as well as the free extract,
were incorporated into yogurt samples in order to evaluate their
role in functional dairy products with chemopreventive (antiangio-
genic) potential.2. Materials and methods
2.1. Standards and reagents
Sodium alginate was provided from Fluka Chemie (Steinheim,
Switzerland) and calcium chloride di-hydrate was obtained from
PanReac AppliChem SAU (Barcelona, Spain). For chromatographic
analysis, HPLC-grade acetonitrile was acquired from Fisher Scien-
tific (Lisbon, Portugal). Ethanol, used as solvent, was acquired from
Pronalab (Lisbon, Portugal). The fatty acids methyl ester (FAME)
reference standard mixture (standard 47885-U) was purchased
from Sigma (St. Louis, MO, USA), as well as the sugar standards.
Apigenin was obtained from Extrasynthesis (Genay Cedex, France)
and sorafenib from Molekula (Newcastle, United Kingdom). Water
was treated in a Milli-Q water purification system (TGI Pure Water
Systems, Greenville, SC, USA). All other chemicals and solvents
were of analytical grade and purchased from common sources.2.2. Plant species and preparation of the extract
A. montana flowers and leafy stems (roughly the upper 15 cm of
the dense clumps produced in spring) are commonly gathered to
be used in traditional preparations. Samples were collected in full
blossom along paths through oak trees. Voucher specimens were
deposited at the Herbarium of the Escola Superior Agrária de Bra-
gança (BRESA) according with Pereira et al. (2014). A sample for
analysis was prepared by putting together the material from differ-
ent specimens, thereafter lyophilized (FreeZone 4.5, Labconco,Kansas City, MO, USA), reduced to a fine dried powder (20 mesh)
and mixed to obtain homogeneity.
The hydroethanolic extract was prepared by stirring the sample
(1 g; 150 rpm) with 30 mL of an ethanol:water mixture (80:20, v/
v), at room temperature, during 1 h, and subsequently filtered
thought a Whatman paper filter No. 4. The solid residue was re-
extracted under the same conditions and the obtained supernatant
mixed with the one previously obtained. The ethanol of the com-
bined extracts was removed by evaporation under reduced pres-
sure (Büchi R-210, Flawil, Switzerland), while the water was
eliminated by lyophilisation.
2.3. VEGFR-2 enzymatic inhibition assay
The A. montana hydroethanolic extract was assessed for VEGFR-
2 inhibition activity using the Z’-LYTE-Tyr1 Peptide assay kit (Invit-
rogen, Cat. PV3190), according to the procedure recommended by
the manufacturer. Briefly, assays were performed with a total of
20 mL in 384-well plates using the fluorescence resonance energy
transfer technology. Each well plate was filled with 2.5 mL of the
tested extract in different concentrations, 5 mL of VEGFR-2 solution
and 2.5 mL of ATP solution, and incubated during 1 h at room tem-
perature. The development reagents (5 mL) were then added to
each well, followed by a stop reagent after a second incubation
of 1 h. The fluorescence was read at 445 nm and 520 nm (excita-
tion 400 nm) using a Biotek FLX800 micro-plate. Gen5TM Software
was used for data analysis. Sorafenib was used as positive control
(Guimarães et al., 2016).
The results were expressed as IC50 values (mg/mL), which repre-
sent the concentration of the sample needed to inhibit 50% of the
VEGFR-2 phosphorylation.
2.4. Microencapsulation of the hydroethanolic extract and
characterization of the microspheres
2.4.1. Microencapsulation
The microspheres were produced by using an atomization/co-
agulation technique previously described by Martins et al., 2014;
Dias et al., 2015 and Ribeiro et al., 2016. Briefly, the encapsulating
material (calcium alginate) was formed by using sodium alginate
and a calcium chloride (CaCl2) as the coagulation agent (source
of Ca2+ ions). The atomization solution was prepared by firstly
mix 50 mg of the A. montana extract with 10 mL of water. After
complete dissolution, 400 mg of sodium alginate were added and
the preparation kept under stirring during 2 h. To produce the
microspheres, a NISCO VarJ30 (Zurich, Switzerland) system, consti-
tuted by a pressure controller, gas source (nitrogen) and a syringe
pump, was used. The previously prepared alginate solution con-
taining the hydroethanolic extract was atomized using the follow-
ing conditions: feed rate of 0.2 mL/min and a nitrogen pressure of
0.1 bar. The atomized droplets upon in contact with the CaCl2 solu-
tion (250 mL at concentration of 4% (w/v)) coagulate promptly fix-
ing the microspheres shape. For total consolidation, they remained
in contact with the coagulation solution during 4 h under stirring
at 200 rpm at room temperature. Finally, microspheres were
recovered by filtration under reduced pressure, washed twice with
water (100 mL), lyophilized and stored in the dark.
2.4.2. Characterization
The microspheres formation was monitored during the coagula-
tion step through Optical microscopy (OM) (initial and final times).
The apparatus was a Nikon Eclipse 50i equipped with a camera
(Nikon Digital Sight, Tokyo, Japan) for image acquisition. The
encapsulation efficiency (EE) was evaluated by HPLC-DAD by
quantifying the non-encapsulated apigenin derivatives, as identi-
fied in the work of Pereira et al. (2014). For that, the coagulation
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responses summed. The encapsulation efficiency was then calcu-
lated according to the following expression:
EE ¼ ½ðMe-t Me-neÞ=ðMe-tÞ  100
in which Me-t represents the theoretical amount of extract, i.e. the
amount of extract used in the microencapsulation process, and
Me-ne corresponds to the non-encapsulated extract.
2.5. Functionalization of yogurt with free and microencapsulated
extracts
2.5.1. Preparation of the yogurt samples
A natural yogurt with 5% fat was selected to test the incorpora-
tion of the free and microencapsulated A. montana extracts. Six
yogurt portions, with 125 g each, were prepared: (i) two samples
of the base yogurt (used as the control sample, i.e. without A. mon-
tana extract); (ii) two samples of yogurt with the free extract (16
mg each); (iii) two samples of yogurt with the microencapsulated
extract (70 mg of lyophilized microspheres each). All the prepared
samples contain an equivalent amount of extract, either in its free
or encapsulated form (the same equivalent ratio of mg extract/g
yogurt). The used amount of extract was twice the IC50 value
(obtained in the VEGFR-2 enzymatic inhibition assay), in accor-
dance with the recommended daily intake of apigenin derivatives
(4–24 mg) (Brasil, 2013). According with our previous results
(Pereira et al., 2014), the A. montana hydroethanolic extract con-
tains 48% (w/w) of apigenin derivatives (Supplementary table).
All the subsequent analyses were performed with lyophilized
yogurt samples obtained immediately after incorporation (right
after the addition of the free or microencapsulated extracts) (t0),
and after 3 days (t3). The t0 and t3 yogurt samples were condi-
tioned at 4 C until analysis.
2.5.2. Nutritional value of the yogurt samples
For the assessment of the nutritional composition of the yogurt
samples, moisture, protein, fat, carbohydrates and ash were deter-
mined following AOAC procedures (AOAC, 2005). The crude protein
content (estimated as N  6.38) was determined using the Kjeldahl
method; the fat was determined by extracting a known weight of
powdered sample with petroleum ether; the ash content was
determined by incineration at 600 ± 15 C; and the total carbohy-
drates obtained by difference. Total energy was calculated as
Energy (kcal) = 4  (protein weight (g) + carbohydrate weight
(g)) + 9  (lipid weight (g)).
Free sugars were determined from defatted samples by HPLC
coupled with a refraction index (RI) detector. The compounds were
identified by chromatographic comparison with injected authentic
standards, and quantification performed by the internal standard
(melezitose) method. Sugars content was expressed in g/100 g of
the yogurt.
Fatty acids were analysed by gas-chromatography coupled with
a flame ionization detector (GC-FID). The identification was made
by comparison with the relative retention times of fatty acid
methyl esters of standards. The results were expressed as relative
percentages.
2.5.3. VEGFR-2 phosphorylation inhibition
The lyophilized yogurt samples (1 g) were extracted with 30 mL
of ethanol: water (80:20 v/v) at room temperature during 1 h
under stirring. The obtained extract was filtered through a What-
man paper filter No. 4 and the remaining solid residue subjected
to an additional extraction. The combined extracts were evapo-
rated under reduced pressure in a rotatory evaporator until com-
plete removal of ethanol. Finally, the evaporated extract was
dissolved in water at a concentration of 8 mg/mL for the evaluationof VEGFR-2 phosphorylation inhibition according with the
methodology described in Section 2.3.
2.6. Statistical analysis
All the assays were carried out in triplicate and the results
expressed as mean values ± standard deviation (SD), and maintain-
ing the decimal places allowed by the magnitude of the standard
deviation. An ANOVA with type III sums of squares was performed
using the general linear model (GLM) procedure. The dependent
variables were analysed using a 2-way ANOVA, with the factors
‘‘functionalizing type” (FT) and ‘‘storage time” (ST). When a statis-
tically significant interaction (FA  ST) was detected, the two fac-
tors were evaluated simultaneously by the estimated marginal
means (EMM) plots for all the levels of each single factor. Alterna-
tively, if no statistical significant interaction was verified, the
means were compared using Tukey’s honest significant difference
(HSD) multiple comparison test to evaluate the FA effect, or by a
t-student test to assess the effect of ST.
All statistical tests were performed at a 5% significance level
using IMB’s SPSS (Statistics for Windows, version 22.0 (IBM Corp.,
Armonk, NY, USA).3. Results and discussion
3.1. VEGFR-2 phosphorylation inhibition by the A. montana extract
In this work, the A. montana hydroethanolic extract was evalu-
ated for its ability to interact with the VEGFR-2 kinase domain,
using an enzymatic fluorescence resonance energy transfer (FRET)
based assay. The results are presented in Fig. 1. The hydroethanolic
extract showed ability to inhibit the enzymatic phosphorylation,
and the obtained IC50 value was 63 ± 3 mg/mL. It was also possible
to observe that the percentage of VEGFR-2 phosphorylation inhibi-
tion increased as the extract concentration increases. The sorafenib
(positive control) showed a lower IC50 value, i.e. a high rate of
VEGFR-2 phosphorylation inhibition. This synthetic drug was
approved by the Food and Drug Administration (FDA) and has been
commonly used for the treatment of pathological angiogenesis
once it binds to receptors on the surface of the endothelial cells
inhibiting, namely, the VEGFR-2. However, it reveals several toxic-
ities for human organism. Diarrhea, fatigue, abdominal pain, hep-
atic toxicity, arterial and venous thrombotic events, gastric
cancer and AVC are some of the side effects ascribed to sorafenib
(Gotink & Verheul, 2010).
It should be also highlighted that A. montana hydroethanolic
extract gave a lower IC50 value (higher VEGFR-2 phosphorylation
inhibition) than the methanolic extract (269 ± 9 mg/mL) and infu-
sion (301 ± 13 mg/mL) obtained from Roman chamomile (Chamae-
melum nobile L.) (Guimarães et al., 2016).
3.2. Microencapsulation of the A. montana extract with alginate
The A. montana hydroethanolic extract was microencapsulated
with alginate using the atomization/coagulation process and fol-
lowing previously optimized conditions, as described in some for-
mer works of the authors (Dias, Barros et al., 2015; Martins et al.,
2014; Ribeiro et al., 2016).
The produced microspheres were analysed by OM immediately
after the atomization process (Fig. 2A) and after 4 h under stirring
in a coagulation solution of calcium chloride (Fig. 2B). After
atomization, the majority of the microspheres showed a character-
istic morphology with a well-defined round shape. However, a few
of them, in particular the ones with low size, revealed pear-like
form. Nevertheless, along the contact period with the coagulation
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Fig. 1. Percentage of VEGFR-2 phosphorylation inhibition as a function of the A.
montana extract concentration.
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increased. Moreover, the microspheres were perfectly individual-
ized (no agglomerates were detected). The size of the microparti-
cles was estimated by OM as ranging between 14 and 88 mm,
size slightly larger than the one obtained in previous works ofFig. 2. Optical microscopy of the microspheres throughout the microencapsulation proce
after coagulation (4 h after the contact with the coagulation solution); (C) microspheres
different magnifications (40, 100 and 400).the authors Martins et al. (2014), Dias, Barros et al. (2015) and
Ribeiro et al. (2016). The lyophilized microparticles can be
observed in Fig. 2C, showing a shape similar to the one observed
for the hydrated forms obtained after the encapsulation process
(round and pear-like form), although they showed a roughened
surface due to the water removal, a consequence of the drying pro-
cess. Additionally, the small brown spots observed in hydrated and
lyophilized microspheres were associated with the presence of the
extract inside the microparticles, in conformity with the work
development by Ribeiro et al. (2016) and Caleja et al. (2016).
The encapsulation efficiency (EE), estimated through an indirect
method based on the quantification of the non-encapsulated api-
genin derivatives by HPLC-DAD, was determined as 100% (the
quantitative analysis of the coagulation and the two wash solu-
tions revealed that the apigenin derivatives were present only in
residual concentrations or absent).
3.3. Yogurts functionalized with free and microencapsulated A.
montana extracts
3.3.1. Nutritional value
The yogurt samples were analysed for their nutritional compo-
sition regarding ash, fat, protein and carbohydrates (including indi-
vidual quantification of galactose and lactose) contents, as well asss. (A) Immediately after atomization (starting point of the coagulation process); (B)
after lyophilization (storage form). In all steps the images are displayed with three
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absent (no added extract), free and microencapsulated forms. The
‘‘storage time” (ST) considered 0 (t0) and 3 days (t3).
Before the study of each individual factor, it is necessary to
analyse the possible interaction (FT  ST) between the various fac-
tors under study. That is, check whether the effect of a given factor
over the different levels of the second follows a specific trend.
Thereby, for all the evaluated parameters, it was aimed to assess
the ST effects regardless of having pure or functionalized yogurts,
as well as evaluating the influence of FT, independently of the
number of days kept in storage.
Table 1 shows the obtained results for macronutrients composi-
tion, individual sugars (galactose and lactose) and energetic value.
It can be verified that the interaction was significant in the case of
fat, protein and ash. Interestingly, these parameters were also not
significantly affected by each individual factor in most cases,
except protein, along ST, and fat, according to FT. Protein content
was higher at initial ST (t0), while fat content was higher in the
functionalized yogurts (both free and microencapsulated forms),
although these differences cannot be unambiguously interpreted,
due to the significant interaction between factors. For all the
remaining parameters, the lack of a significant interaction allowedTable 1
Nutritional value of the control yogurts and of those containing the extract (free or micro
Moisture (g/
100 g)
Fat (g/
100 g)
Storage time (ST) 0 days 88 ± 1 2.6 ± 0.2
3 days 89 ± 1 2.7 ± 0.2
p-value (n = 27) t-Student test 0.054 0.065
Functionalization type
(FT)
Absent 88 ± 1 2.4 ± 0.1
Free extract 89 ± 1 2.9 ± 0.1
Microencapsulated
extract
89 ± 1 2.7 ± 0.1
p-value (n = 18) Tukey’s HSD test 0.352 <0.001
ST  FT (n = 54) p-value 0.756 0.007
Table 2
Main fatty acids and total saturated, monounsaturated and polyunsaturated fatty acids (re
microencapsulated) at storage times of 0 and 3 days (mean ± SD).
C4:0 C6:0 C10:0 C12:0
Storage time(ST) 0 days 2 ± 1 2.4 ± 0.4 3.3 ± 0.2 3.7 ± 0
3 days 3 ± 1 2.8 ± 0.2 3.2 ± 0.2 3.5 ± 0
p-value (n = 27) t-Student test <0.001 <0.001 0.059 <0.001
Functionalization
type (FT)
Absent 2.6 ± 0.4 2.7 ± 0.2 3.2 ± 0.1 3.5 ± 0
Free extract 2.3 ± 0.5 2.3 ± 0.4 3.5 ± 0.1 3.8 ± 0
Microencapsulated
extract
3.6 ± 0.2 2.8 ± 0.2 3.1 ± 0.2 3.6 ± 0
p-value (n = 18) Tukey’s HSD test <0.001 <0.001 <0.001 0.001
ST  FT (n = 54) p-value <0.001 <0.001 0.004 <0.001
Butiric acid (C4:0), caproic acid (C6:0); capric acid (C10:0); lauric acid (C12:0); myristic
acid (C18:2); SFA - Saturated fatty acids; MUFA - Monounsaturated fatty acids; PUFA - Pol
detected in minor amounts (each one <2%).
Table 3
Percentage of VEGFR-2 phosphorylation inhibition of the yogurt samples functionalized w
without extracts).
Storage time (days)
Free extract 0
3
Microencapsulated extract 0
3performing multiple comparisons for each individual factor, but
their individual effects were only significant (p-value < 0.05) in
the case of lactose (for ST), which proved to be significantly higher
at t0, when compared to the value obtained at t3. All other param-
eters remained approximately invariable for both factors in study
(ST and FT).
The results obtained are in agreement with other reports on
yogurts (Caleja, Barros et al., 2016; Serafeimidou, Zlatanos,
Kritikos, & Tourianis, 2013). According with Serafeimidou et al.
(2013), the yogurts prepared with cow and sheep milk had similar
amounts of moisture and proteins, but lower ash content in com-
parison with the cow yogurt samples studied in the present work.
However, ash values were in accordance with the ones reported by
Caleja, Barros et al. (2016) for yogurts fortified with chamomile
(Matricaria recutita L.) and fennel (Foeniculum vulgare Mill.) aque-
ous extracts. Furthermore, the same composition in galactose and
lactose was described.
In the case of fatty acids (Table 2) the interaction between the
factors was significant for all the analysed molecules. Thus, it is
not possible to indicate unequivocal changes induced by each
one of the factors. Nevertheless, the performed multiple compar-
isons indicated some general trends. The increase in ST induced aencapsulated) at storage times of 0 and 3 days (mean ± SD).
Protein (g/
100 g)
Carbohydrates (g/100 g) Ash (g/
100 g)
Energy (kcal/
100 g)
Galactose Lactose Total
4.0 ± 0.1 0.5 ± 0.1 3.9 ± 0.4 4 ± 1 0.6 ± 0.1 57 ± 2
3.8 ± 0.1 0.6 ± 0.1 3.4 ± 0.4 4 ± 1 0.6 ± 0.1 57 ± 3
<0.001 0.284 <0.001 0.108 0.062 0.394
3.9 ± 0.2 0.6 ± 0.1 3.7 ± 0.4 4 ± 1 0.6 ± 0.1 56 ± 2
3.9 ± 0.1 0.5 ± 0.1 3.7 ± 0.4 4 ± 1 0.5 ± 0.1 58 ± 3
3.9 ± 0.1 0.6 ± 0.1 3.6 ± 0.5 4 ± 1 0.6 ± 0.1 57 ± 2
0.762 0.205 0.801 0.308 0.051 0.090
<0.001 0.214 0.506 0.506 0.007 0.819
lative percentage) in the control yogurts and in those containing the extract (free or
C14:0 C16:0 C18:0 C18:1 C18:2 SFA MUFA PUFA
.1 11 ± 1 31 ± 1 11 ± 1 24 ± 1 3.1 ± 0.2 69 ± 1 27 ± 1 4.6 ± 0.2
.2 11 ± 1 30 ± 1 11 ± 1 24 ± 1 3.2 ± 0.2 68 ± 1 27 ± 1 4.7 ± 0.4
0.062 0.002 0.485 0.473 0.702 0.216 0.345 0.160
.2 11 ± 1 30 ± 1 12 ± 1 24 ± 1 3.2 ± 0.2 68 ± 1 27 ± 1 4.8 ± 0.3
.1 11 ± 1 31 ± 1 11 ± 1 24 ± 1 3.1 ± 0.2 69 ± 1 27 ± 1 4.5 ± 0.3
.1 11 ± 1 30 ± 1 11 ± 1 24 ± 1 3.1 ± 0.2 69 ± 1 27 ± 1 4.6 ± 0.3
0.055 0.061 <0.001 0.080 0.085 0.064 0.236 0.056
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
acid (C14:0); palmitic acid (C16:0); stearic acid (C18:0); oleic acid (C18:1); linoleic
yunsaturated fatty acids. In addition to the tabled fatty acids, twenty more were also
ith A. montana extracts (free and microencapsulated) relative to the control (yogurt
VEGFR-2 phosphorylation inhibition
1 mg/mL 10 mg/mL 100 mg/mL
0.99 ± 0.01 1.80 ± 0.03 5.10 ± 0.03
2.44 ± 0.06 3.12 ± 0.05 0.85 ± 0.05
1.31 ± 0.06 1.84 ± 0.07 4.13 ± 0.03
1.09 ± 0.02 3.05 ± 0.01 0
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reductions in C12:0 and C16:0 percentages. The remaining fatty
acids proportions remained nearly constant. In what concerns FT
effect, yogurts incorporated with the microencapsulated extract
showed higher values of C4:0 and C6:0, while those incorporated
with the free extract showed higher percentages of C10:0 and
C12:0. Finally, the control yogurts (yogurts absent of extract)
showed slightly higher percentages of C18:0. All the other fatty
acids, kept their overall percentages roughly constant, either in
response to ST and FT factors, which indicates that the fatty acids
profile suffer only slight changes. The general proportions (SFA > -
MUFA > PUFA) are in general agreement with previous works
(Serafeimidou et al., 2013).3.3.2. Evaluation of the VEGFR-2 phosphorylation inhibition
The yogurt functionalized with the free and microencapsulated
extracts were evaluated for their potential VEGFR-2 phosphoryla-
tion inhibition. In general, yogurt samples added with the extract,
in both free and microencapsulated forms, revealed very low inhi-
bition ability (low inhibition percentages) (Table 3).
The absence, or scarcity, of VEGFR-2 phosphorylation inhibition
observed for the yogurt samples prepared with the free extract was
not foreseen based on its ascribed potential and the used amount
(2  IC50), which was also chosen to guarantee the recommended
daily intake of apigenin derivatives. Due to this observation, a sam-
ple yogurt 20-fold more concentrate was prepared. The main
objective was to evaluate the influence of the extract concentration
on the VEGFR-2 phosphorylation activity of the prepared yogurt.
However, the obtained results (data not shown) revealed, once
again, very low inhibition percentages pointing out for the extract
degradation and/or bioactivity loss. In fact, proteins, the predomi-
nant constituents of the yogurt matrix, present ability to conjugate
with phenolic compounds (major constituents of the hydroethano-
lic extract) leading to bioavailability loss (Ozdal, Capanoglu, &
Altay, 2013).
When the microencapsulated forms were used, the determined
VEGFR-2 phosphorylation inhibition was also absent, or scarce. In
fact, the extract was, in this case, protected inside the alginate
microspheres, material reported as stable in acid pH conditions
(Cui, Goh, Kim, Choi, & Lee, 2000), thus effective to protect it in
contact with the yogurt, an acidic food matrix (Caleja, Barros
et al., 2016). This behavior was also reported by Ribeiro et al.
(2016) in cottage cheese functionalized with rosemary extracts
microencapsulated in alginate microspheres. This procedure is, in
principle, effective to avoid the loss of bioavailability during the
shelf life of the product, thus until its ingestion and release in slight
alkaline medium (intestinal conditions) due to the disruption of
the alginate microparticles.4. Conclusions
A. montana hydroethanolic extract, an extract rich in apigenin
derivatives (weight content of 48%, as reported in a previous work
of the group (Pereira et al., 2014), revealed VEGFR-2 phosphoryla-
tion inhibition ability. The extract was successfully encapsulated in
an alginate matrix, being incorporated in yogurts presenting nutri-
tional properties similar to the ones incorporated with free extract
or without extract (control sample). However, after incorporation
of the free extract in yogurts, the antiangiogenic activity was not
effective since only minor antiangiogenic ability was detected,
independently of the used concentration. For the microencapsu-
lated forms, and based on the successful applied microencapsula-
tion process, the extract protection in acidic medium was
expected, thus supporting the absence of the antiangiogenic activ-
ity of the produced yogurts. Accordingly, more studies are neces-sary to understand the stability of the bioactive compounds of
the extract, namely their interactions with the food matrix con-
stituents and behavior (for both free andmicroencapsulated forms)
under simulated gastrointestinal conditions in order to develop
functional foods with effective chemopreventive effects against
pathological angiogenesis.
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